Heidy King-Jones

CIK: 0001794898

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)10 (66.7%)

Position reduction

Option Exercises (M)3 (20.0%)

Derivative conversions

Awards (A)2 (13.3%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

SYRE

Spyre Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (15 total)

SYRE
Spyre Therapeutics, Inc.
Oct 1, 2026
Exercise(M)
Direct
28.9K shares at avg. $14.50$420K
SYRE
Spyre Therapeutics, Inc.
Oct 1, 2026
Sale(S)
Direct
16.6K shares at avg. $90.35$1.5M
SYRE
Spyre Therapeutics, Inc.
Oct 1, 2026
Sale(S)
Direct
7.2K shares at avg. $91.35$660K
SYRE
Spyre Therapeutics, Inc.
Oct 1, 2026
Sale(S)
Direct
2.1K shares at avg. $92.70$195K
SYRE
Spyre Therapeutics, Inc.
Oct 1, 2026
Sale(S)
Direct
2.6K shares at avg. $93.46$243K
SYRE
Spyre Therapeutics, Inc.
Oct 1, 2026
Sale(S)
Direct
400 shares at avg. $89.24$36K
SYRE
Spyre Therapeutics, Inc.
Sep 2, 2026
Sale(S)
Direct
400 shares at avg. $90.00$36K
SYRE
Spyre Therapeutics, Inc.
Sep 2, 2026
Exercise(M)
Direct
400 shares at avg. $14.50$6K
SYRE
Spyre Therapeutics, Inc.
Sep 1, 2026
Exercise(M)
Direct
28K shares at avg. $14.50$406K
SYRE
Spyre Therapeutics, Inc.
Sep 1, 2026
Sale(S)
Direct
4.8K shares at avg. $86.40$419K
SYRE
Spyre Therapeutics, Inc.
Sep 1, 2026
Sale(S)
Direct
16.5K shares at avg. $87.20$1.4M
SYRE
Spyre Therapeutics, Inc.
Sep 1, 2026
Sale(S)
Direct
6.2K shares at avg. $88.17$547K
SYRE
Spyre Therapeutics, Inc.
Sep 1, 2026
Sale(S)
Direct
400 shares at avg. $89.38$36K
SYRE
Spyre Therapeutics, Inc.
Jan 9, 2026
Award(A)
Stock Option (Right to Buy)
Direct
140K shares-
SYRE
Spyre Therapeutics, Inc.
Jan 15, 2025
Award(A)
Stock Option (Right to Buy)
Direct
95.5K shares-

		Type	Shares	Price		Ownership
Oct 1, 2026	SYRE Spyre Therapeutics, Inc.	Exercise(M)	28,933	$14.50	$419,529	Direct
Oct 1, 2026	SYRE Spyre Therapeutics, Inc.	Sale(S)	16,605	$90.35	$1,500,262	Direct
Oct 1, 2026	SYRE Spyre Therapeutics, Inc.	Sale(S)	7,228	$91.35	$660,278	Direct
Oct 1, 2026	SYRE Spyre Therapeutics, Inc.	Sale(S)	2,100	$92.70	$194,670	Direct
Oct 1, 2026	SYRE Spyre Therapeutics, Inc.	Sale(S)	2,600	$93.46	$242,996	Direct
Oct 1, 2026	SYRE Spyre Therapeutics, Inc.	Sale(S)	400	$89.24	$35,696	Direct
Sep 2, 2026	SYRE Spyre Therapeutics, Inc.	Sale(S)	400	$90.00	$36,000	Direct
Sep 2, 2026	SYRE Spyre Therapeutics, Inc.	Exercise(M)	400	$14.50	$5,800	Direct
Sep 1, 2026	SYRE Spyre Therapeutics, Inc.	Exercise(M)	27,999	$14.50	$405,986	Direct
Sep 1, 2026	SYRE Spyre Therapeutics, Inc.	Sale(S)	4,845	$86.40	$418,608	Direct
Sep 1, 2026	SYRE Spyre Therapeutics, Inc.	Sale(S)	16,548	$87.20	$1,442,986	Direct
Sep 1, 2026	SYRE Spyre Therapeutics, Inc.	Sale(S)	6,206	$88.17	$547,183	Direct
Sep 1, 2026	SYRE Spyre Therapeutics, Inc.	Sale(S)	400	$89.38	$35,752	Direct
Jan 9, 2026	SYRE Spyre Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	140,000	-	-	Direct
Jan 15, 2025	SYRE Spyre Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	95,500	-	-	Direct

1-15 of 15 transactions

About King-Jones Heidy

King-Jones Heidy (SEC CIK 0001794898) files insider reports with the SEC as Officer of Spyre Therapeutics, Inc. (SYRE).

Signal8 holds 4 ownership filings by King-Jones Heidy, all Form 4s, filed between Jan 17, 2025 and Oct 2, 2026. Those filings report 15 transactions, from Jan 15, 2025 to Oct 1, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on King-Jones Heidy's filings is in WALTHAM, MA.

Recent filings by King-Jones Heidy

Oct 1, 2026: Option exercise of SYRE shares (Form 4, code M).
Oct 1, 2026: Open-market sales of SYRE shares (5 lines, Form 4, code S).
Sep 2, 2026: Open-market sale of SYRE shares (Form 4, code S).
Sep 2, 2026: Option exercise of SYRE shares (Form 4, code M).
Sep 1, 2026: Option exercise of SYRE shares (Form 4, code M).

Other insiders filing for Spyre Therapeutics, Inc. (SYRE)

Turtle Cameron, Chief Executive Officer
Burrows Scott L, Chief Financial Officer
Albers Jeffrey W., Director
Sloan Sheldon, Chief Medical Officer
Fairmount Funds Management LLC, Director
HENDERSON MICHAEL THOMAS, Director

How to read Form 4 transaction codes